Display options
Cite
Wirtz MR, van den Brink DP, Roelofs JJTH, et al. Therapeutic application of recombinant human ADAMTS-13 improves shock reversal and coagulation status in a trauma hemorrhage and transfusion rat model. Intensive Care Med Exp. 2020;8:42doi: 10.1186/s40635-020-00328-w.
Wirtz, M. R., van den Brink, D. P., Roelofs, J. J. T. H., Goslings, J. C., & Juffermans, N. P. (2020). Therapeutic application of recombinant human ADAMTS-13 improves shock reversal and coagulation status in a trauma hemorrhage and transfusion rat model. Intensive care medicine experimental, 842. https://doi.org/10.1186/s40635-020-00328-w
Wirtz, Mathijs R, et al. "Therapeutic application of recombinant human ADAMTS-13 improves shock reversal and coagulation status in a trauma hemorrhage and transfusion rat model." Intensive care medicine experimental vol. 8 (2020): 42. doi: https://doi.org/10.1186/s40635-020-00328-w
Wirtz MR, van den Brink DP, Roelofs JJTH, Goslings JC, Juffermans NP. Therapeutic application of recombinant human ADAMTS-13 improves shock reversal and coagulation status in a trauma hemorrhage and transfusion rat model. Intensive Care Med Exp. 2020 Dec 18;8:42. doi: 10.1186/s40635-020-00328-w. PMID: 33336308; PMCID: PMC7746419.
Copy Download .nbib Format: NLM
Share it on

Intensive Care Med Exp. 2020 Dec 18;8:42. doi: 10.1186/s40635-020-00328-w.

Therapeutic application of recombinant human ADAMTS-13 improves shock reversal and coagulation status in a trauma hemorrhage and transfusion rat model.

Intensive care medicine experimental

Mathijs R Wirtz, Daan P van den Brink, Joris J T H Roelofs, J Carel Goslings, Nicole P Juffermans

Affiliations

  1. Department of Intensive Care Medicine, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands. [email protected].
  2. Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands. [email protected].
  3. Department of Trauma Surgery, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands. [email protected].
  4. Department of Intensive Care Medicine, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands.
  5. Department of Trauma Surgery, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands.
  6. Department of Pathology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands.
  7. Department of Trauma Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
  8. Laboratory of Experimental Intensive Care and Anesthesiology, Amsterdam University Medical Centers, location Academic Medical Center, Amsterdam, The Netherlands.

PMID: 33336308 PMCID: PMC7746419 DOI: 10.1186/s40635-020-00328-w

Abstract

INTRODUCTION: In hemorrhaging trauma patients, the endothelium is activated, resulting in excessive endothelial synthesis of von Willebrand Factor (vWF), which may enhance micro-thrombi formation, resulting in obstruction of the microcirculation and endothelial injury, aggravating bleeding, as well as contributing to organ failure. Under normal conditions, vWF is cleaved by the metalloprotease ADAMTS-13. After trauma, ADAMTS-13 levels are reduced.

OBJECTIVES: To assess whether recombinant human ADAMTS-13 inhibits endothelial injury and organ failure in a rat trauma-transfusion model.

METHODS: Blood products were prepared from syngeneic rat blood according to blood bank standards. Polytrauma was induced in rats by crush injury to the intestines and liver and by fracture of the femur. The rats were hemorrhaged until a mean arterial pressure (MAP) of 40 mmHg was reached. Rats were randomized to receive transfusion of RBCs, FFPs, and platelets in a 1:1:1 ratio to achieve a MAP of 70 mmHg, with or without the addition of ADAMTS-13 (50 μg/kg). Blood samples were assessed for biochemistry and rotational thromboelastometry (ROTEM). Syndecan-1 and VE-cadherin levels were measured as a reflection of endothelial integrity. The amount of leakage of dextran-FITC from the vascular system to the parenchyma in lungs was quantified. To assess inflammation, IL-6 and IL-8 levels were determined. Organ damage was assessed by histopathology.

RESULTS: All rats were severely shocked, with no significant differences in shock parameters between groups. Rats treated with ADAMTS-13 showed signs of a more effective shock reversal (higher blood pressure, lower lactate levels) compared to controls. Also, ROTEM parameters of clot formation in rats receiving ADAMTS-13 improved compared to controls, which was mainly platelet-dependent. Syndecan-1 levels relative to baseline trended to be lower in ADAMTS-13 treated rats compared to controls (107 vs 149%, p = 0.08). ADAMTS-13 reduced albuminuria (1.7 vs 4.4 g/L, p < 0.01) and organ-specific inflammation (pulmonary IL-6 243 vs 369 pg/mL, p = 0.08; splenic IL-6 253 vs 307, p = 0.03) compared to controls, but did not improve histopathological scores.

CONCLUSIONS: The use of ADAMTS-13 in a rat trauma-transfusion model improves parameters of shock, platelet-driven coagulation, endothelial damage, and organ inflammation. These results suggest that ADAMTS-13 is important in mediating outcome of trauma. Whether ADAMTS-13 can be used as a therapeutic adjunct to treat bleeding trauma patients remains to be determined.

Keywords: ADAMTS-13; Coagulopathy; Hemorrhage; Resuscitation; Trauma

References

  1. J Trauma Acute Care Surg. 2017 Feb;82(2):293-301 - PubMed
  2. Crit Care. 2019 Mar 9;23(1):77 - PubMed
  3. Am J Clin Pathol. 2011 Sep;136(3):364-70 - PubMed
  4. Clin Chim Acta. 2015 Feb 2;440:87-92 - PubMed
  5. Curr Mol Med. 2010 Mar;10(2):236-48 - PubMed
  6. Thromb Haemost. 2018 Apr;118(4):676-687 - PubMed
  7. PLoS One. 2011;6(8):e23530 - PubMed
  8. Transfus Apher Sci. 2006 Dec;35(3):235-8 - PubMed
  9. Transfusion. 2019 Jan;59(1):134-145 - PubMed
  10. Intensive Care Med. 2015 Feb;41(2):239-47 - PubMed
  11. Int J Clin Exp Pathol. 2014 Jun 15;7(7):3818-26 - PubMed
  12. Front Med (Lausanne). 2015 Apr 24;2:24 - PubMed
  13. Blood. 2018 Sep 6;132(10):1075-1084 - PubMed
  14. Microcirculation. 2019 Feb;26(2):e12483 - PubMed
  15. Front Med (Lausanne). 2018 Apr 18;5:91 - PubMed
  16. PLoS One. 2017 Dec 20;12(12):e0189837 - PubMed
  17. Nephron Clin Pract. 2014;128(3-4):373-80 - PubMed
  18. Blood. 2013 Jan 10;121(2):270-7 - PubMed
  19. J Am Coll Surg. 2017 Sep;225(3):419-427 - PubMed
  20. Blood. 2013 Apr 25;121(17):3502-10 - PubMed
  21. Anesthesiology. 2010 Jul;113(1):92-103 - PubMed
  22. Blood. 2017 Nov 9;130(19):2055-2063 - PubMed
  23. Medicine (Baltimore). 2016 Apr;95(16):e3374 - PubMed
  24. Lancet. 2014 Oct 18;384(9952):1455-65 - PubMed
  25. Ann Surg. 2011 Aug;254(2):194-200 - PubMed
  26. Blood. 2010 Aug 26;116(8):1360-8 - PubMed
  27. J Thromb Haemost. 2015 Nov;13(11):2053-62 - PubMed
  28. Br J Surg. 2017 Feb;104(3):222-229 - PubMed
  29. Stroke. 2015 Sep;46(9):2647-53 - PubMed
  30. J Crit Care. 2018 Apr;44:229-237 - PubMed
  31. Crit Care. 2015 Apr 15;19:163 - PubMed

Publication Types